IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo

By V. Carrière, Lucie Roussel, N. Ortéga, D. Lacorre, Laure Americh, L. Aguilar, G. Bouche, J. Girard. Proceedings of the National Academy of Sciences of the United States of America, 2007

1,035 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Immunology

View Paper: https://www.semanticscholar.org/paper/d9fd932bf3e013031b6a60554fa247343724499d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

In Immunology

Citations in the corpus

Sterile inflammation: sensing and reacting to damage (2010, background): “IL-33 is highly expressed within endothelial cells in the synovium of patients with rheumatoid arthriti”
IL‐33 induces IL‐13 production by mouse mast cells independently of IgE‐FcεRI signals (2007, background): “Like IL-1 [10], some of the biological activities of IL-33 may also reflect the ability of a precursor/intracellular form of the cytokine to function as an intracrine chromatin-associated nuclear factor, which can regulate transcription [11].”
The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel ‘Alarmin’? (2008, background): “IL-33 (initially designated NF-HEV for ‘‘Nuclear Factor from High Endothelial Venules’’ [1]) is the most recent addition to the IL-1 family [2,3].”
Genome-wide association studies: what do they teach us about asthma and chronic obstructive pulmonary disease? (2009, background): “The potential importance of this receptor, which can be induced by proinflammatory stimuli and is likely involved in the function of helper T cells, was described in previous functional and human studies ( 6 , 7).”
A Large-Scale, Consortium-Based Genomewide Association Study of Asthma (2010, neutral): “ALSPAC United Kingdom 607 607 (57) — 609 609 (51) — B58C United Kingdom 445 213 (56) 232 (38) 420 200 (44) 220 (50) BAMSE Sweden 239 239 (63) — 246 246 (48) — BUSSELTON Australia 398 188 (51) 210 (33) 809 390 (45) 419 (41) CAPPS and SAGE Canada 88 88 (66) — 182 182 (51) — ECRHS Multiple countries 66”
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. (2011, background): “(9) With the infiltration of myeloid cells (monocytes and neutrophils), there is expanded inflammation, which extends beyond the initial area of ischemia.”
The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1 (2009, methodology): “Proteins were fractionated by SDS/PAGE, electroblotted, and detected with mAbs to myc-epitope tag (9E10, 1:1,000; Sigma), IL-33 (Nessy-1, 1:1,000; Alexis Biochemicals; 305B, 1:1,000; Alexis Biochemicals), or PARP (1:2,000; BD PharMingen), or rabbit antiserum to IL-33Nter (IL-331–15, 1:400) (3, 5), I”
Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. (2009, background): “IL-33 is a nuclear protein that has been reported to possess activity as a regulator of transcription (Carriere et al., 2007).”
The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress (2008, background): “Interestingly, IL-33 is a nuclear protein and it is thought to be released by dying cells, acting as a danger signal (29).”